xMAP® MultiFlex™ Zika RNA Assay

For Use Under the Emergency Use Authorization (EUA) Only.
**For Use Under the Emergency Use Authorization (EUA) Only.**

**For use with MAGPIX® or Luminex® 200™ Instruments.**

Refer to Table 1, "Reagents Supplied in the Kit and Storage Conditions" for reagent storage conditions.

<table>
<thead>
<tr>
<th>Kit Components</th>
<th>REF</th>
</tr>
</thead>
<tbody>
<tr>
<td>xMAP® MultiFLEX™ Zika RNA Assay</td>
<td>∑ 100 MBP-EUA-01</td>
</tr>
<tr>
<td>TDAS LSM Software</td>
<td>CN-SW56-01</td>
</tr>
</tbody>
</table>

**Symbols**

| 5.1.5* | Batch Code | Indicates the manufacturer's batch code so that the batch or lot can be identified. |
| 5.3.2‡ | Keep away from sunlight. | Indicates a medical device that needs protection from light sources. |
| 5.1.6* | Catalog(ue) Number | Indicates the manufacturer's catalogue number so that the medical device can be identified. |
| 5.4.4* | Caution | Indicates the need for the user to consult the instructions for use for important cautionary information such as warnings and precautions that cannot, for a variety of reasons, be presented on the medical device itself. |
| 5.1.1* | Manufacturer / Date of manufacture | Indicates the medical device manufacturer, as defined in EU Directives 90/385/EEC, 93/42/EEC and 98/79/EC. |
| 5.5.5* | Contains Sufficient for <n> Tests | Indicates the total number of IVD tests that can be performed with the IVD kit reagents. |
| 5.4.3* | Consult instructions for use | Indicates the need for the user to consult the instructions for use. |
| 5.1.3* | Date of manufacture | Indicates the date when the medical device was manufactured. |
| 5.3.7* | Temperature Limit | Indicates the temperature limits to which the medical device can be safely exposed. |
| † | For use only under Emergency Use Authorization |

| † Rx Only | Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner (U.S. Only) | 5.5.1* | In vitro diagnostic medical device |

* ANSI/AAMI/ISO 15223-1:2012, Medical devices—Symbols to be used with medical device labels, labeling, and information to be supplied—Part 1: General requirements.
‡ ANSI/AAMI/ISO 15223-1:2012, Medical devices—Symbols to be used with medical device labels, labeling, and information to be supplied—Part 1: General requirements.
Standard Terms and Conditions For Use of Assay Product

By opening the packaging containing this assay product or cassette ("Product") or by using such Product in any manner, you are consenting and agreeing to be bound by the following terms and conditions. You are also agreeing that the following terms and conditions constitute a legally valid and binding contract that is enforceable against you. If you do not agree to all of the terms and conditions set forth below, you must promptly return the Product for a full refund prior to using them in any manner.

1. **Acceptance** - All sales are subject to and expressly conditioned upon the terms and conditions contained herein, and upon Buyer's assent thereto. No variation of these terms and conditions shall be binding upon Luminex Corporation ("LUMINEX") unless agreed to in writing and signed by an authorized representative of LUMINEX. For purposes of this agreement, "Seller" shall mean either Luminex, if the Product is purchased directly from Luminex, or a Luminex authorized reseller. Buyer, by accepting the Product shall be deemed to have assented to the terms and conditions set forth herein, notwithstanding any terms contained in any prior or later communications from Buyer and whether or not Seller shall specifically or expressly object to any such terms.

2. **Warranties** – Notwithstanding Buyer's acceptance thereof, if Product is purchased directly from Luminex, Luminex warrants that the Product shall conform to the quantity and content stated on the label and perform in all material respects consistent with Product specifications accompanying the Product until the expiration date set forth on the Product label. If Product is purchased from a Luminex authorized reseller, any warranty obligations shall be provided in writing directly by such Luminex authorized reseller to Buyer. This warranty is exclusive and Luminex makes no other warranty, express or implied, including, without limitation, any implied warranty of merchantability, fitness for a particular purpose, or non-infringement. Seller's warranties made in connection with this sale shall not be effective if Seller has determined, in its sole discretion, that Buyer has misused the Product in any manner, has failed to use the Product in accordance with industry standards or practices, or has failed to use the Product in accordance with instructions, if any, furnished by Seller.

Buyer's exclusive remedy with respect to Product proved to Seller's satisfaction to be defective or nonconforming shall be replacement of such products without charge or refund of the purchase price, in Seller's sole discretion, upon the return of such products in accordance with Seller's instructions. Neither Seller nor Luminex nor its affiliates shall in any event be liable for incidental, consequential or special damages of any kind resulting from any use or failure of the Product, even if Seller or Luminex or its affiliate has been advised of the possibility of such damages, including, without limitation, liability for loss of work in progress, down time, loss of revenue or profits, failure to realize savings, loss of products of Buyer or other use or any liability of Buyer to a third party on account of such loss, or for any labor or any other expense, damage or loss occasioned by such product including personal injury or property damage unless such personal injury or property damage is caused by Seller's gross negligence.

3. **Buyer's Use of Product** – Buyer agrees that no rights or licenses under Luminex's patents shall be implied from the sale of the Product, except as expressly provided herein or as specifically agreed to in writing by Luminex, and Buyer does not receive any right under Luminex's patent rights hereunder. Buyer acknowledges and agrees that the Product is sold and licensed only for use with Luminex's instrumentation. In order to maintain the quality of the Product, Buyer may use this Product only once on a single use basis and shall not reuse this Product under any circumstances. Buyer further acknowledges that the Product has not received clearance from the United States Food and Drug Administration or other federal, state or local regulatory agencies and has not been tested by Seller or Luminex for safety or efficacy in food, drug, medical device, cosmetic, commercial or any other use, unless otherwise stated on the Product label or in Seller's technical specifications or material data sheets furnished to Buyer. Buyer expressly represents and warrants to Seller that Buyer will use the Product in accordance with the Product label, if applicable, and will properly test and use any Product in accordance with the practices of a reasonable person who is an expert in the field and in strict compliance with the United States Food and Drug Administration and all applicable domestic and international laws and regulations, now and hereinafter enacted.

Buyer hereby grants to Luminex a nonexclusive, worldwide, unrestricted, royalty-free, fully paid-up license, with the right to grant and authorize sublicenses, under any and all patent rights in inventions comprising modifications, extensions, or enhancements made by Buyer to the product or to the manufacture or use of the Product ("improvement patents"), to make, have made, use, import, offer for sale or sell any and all of the Product; exploit...

Buyer has the responsibility and hereby expressly assumes the risk to verify the hazards and to conduct any further research necessary to learn the hazards involved in using the Product. Buyer also has the duty to warn Buyer’s customers, employees, agents, assigns, officers, successors and any auxiliary or third party personnel (such as freight handlers, etc.) of any and all risks involved in using or handling the Product. Buyer agrees to comply with instructions, if any, furnished by Seller or Luminex relating to the use of the Product and to not misuse the Product in any manner. Buyer shall not reverse engineer, decompile, disassemble or modify the Product. Buyer acknowledges that Luminex retains ownership of all patents, trademarks, trade secrets and other proprietary rights relating to or residing in the Product and Buyer receives no rights to such intellectual property rights by virtue of its purchase of Product other than as expressly set forth herein. Buyer shall have no right to use any trademarks owned or licensed to Luminex without the express written permission of Luminex.

4. **Buyer's Representations, Release and Indemnity** - Buyer represents and warrants that it shall use the Product in accordance with Paragraph 3, “Buyer's Use of Product,” and that any such use of the Product will not violate any law, regulation, judicial order or injunction. Buyer agrees to release, discharge, disclaim and renounce any and all claims, demands, actions, causes of action and/or suits in law or equity, now existing or hereafter arising, whether known or unknown, against Seller and Luminex, and their respective officers, directors, employees, agents, successors and assigns (collectively the “Released Parties”), with respect to the use of the Product. Buyer agrees to indemnify and hold harmless the Released Parties from and against any suits, losses, claims, demands, liabilities, costs and expenses (including attorney, accounting, expert witness, and consulting fees) that any of the Released Parties may sustain or incur as a result of any claim against such Released Party based upon negligence, breach of warranty, strict liability in tort, contract or any other theory of law or equity arising out of, directly or indirectly, the use of the Product or by reason of Buyer's failure to perform its obligations contained herein. Buyer shall fully cooperate with the Released Parties in the investigation and determination of the cause of any accident involving the Product which results in personal injury or property damage and shall make available to the Released Parties all statements, reports, recordings and tests made by Buyer or made available to Buyer by others.

5. **Patent Disclaimer** – Neither Seller nor Luminex warrants that the use or sale of the Product will not infringe the claims of any United States or other patents covering the Product itself or the use thereof in combination with other products or in the operation of any process.

89-30000-00-187 Rev C
End-User License Agreement (EULA) for Luminex® Software

This Luminex End-User License Agreement (“EULA”) is a legal agreement between you (either an individual or a single entity, also referred herein as “you”), the end-user and Luminex Corporation and its affiliates (collectively, “Luminex”) regarding the use of Luminex or third party software product provided to you by Luminex or its authorized reseller, which includes computer software, scripts, algorithms, and online or electronic documentation and may include associated media and printed materials (if any) (“SOFTWARE”). The terms also apply to any updates, supplements, web content or Internet-based services, such as remote access.

BY USING, INSTALLING, OR ACCESSING THE SOFTWARE, YOU ACCEPT THESE TERMS. IF YOU DO NOT ACCEPT THESE TERMS, DO NOT USE, INSTALL, AND/OR ACCESS THE SOFTWARE. INSTEAD, RETURN IT TO LUMINEX OR THE LUMINEX AUTHORIZED RESELLER FROM WHICH YOU PURCHASED OR OBTAINED THE SOFTWARE (IF APPLICABLE, FOR A REFUND OR CREDIT). IF YOU COMPLY WITH THESE LICENSE TERMS, YOU HAVE THE RIGHTS TO USE THE SOFTWARE AS SPECIFICALLY SET FORTH BELOW.

1. **OVERVIEW.** The SOFTWARE is protected by copyright laws and international copyright treaties, as well as other intellectual property laws and treaties. The SOFTWARE is licensed, not sold.

2. **ADDITIONAL LICENSING REQUIREMENTS AND/OR USE RIGHTS.**
   a. **Trial and Conversion.** Some or all of the SOFTWARE may be licensed on a trial basis. Your rights to use trial SOFTWARE are limited to the trial period. The trial SOFTWARE and length of the trial period are set forth during the activation process or otherwise set forth in a written agreement between Luminex and you. The SOFTWARE may be used for evaluation purposes only during the trial period and not for any commercial use, including without limitation to any diagnostic use. You may have the option to convert your trial rights to perpetual rights. Conversion options will be presented to you at the expiration of your trial period.
   b. **Activation.** For certain SOFTWARE, you can activate the SOFTWARE by obtaining a license key provided by Luminex Technical Support at support@luminexcorp.com or 1-877-785-2323 or 1-512-381-4397.
   c. **Branding.** You may only add additional branding or other graphics to SOFTWARE with Luminex's express written consent. For certain SOFTWARE, Luminex may permit you to upload your logo onto the SOFTWARE pursuant to the instructions and terms provided by Luminex.
   d. **Upgrades.** You may only obtain updates or upgrades for the SOFTWARE from Luminex Technical Support at orders@luminexcorp.com or authorized resellers. For certain SOFTWARE, Luminex may permit downloading updates or upgrades from a Luminex authorized Website. For more information on obtaining updates from authorized resellers, see http://www.luminexcorp.com.

3. **GRANT OF LICENSE.** Subject to the terms and conditions of this EULA, Luminex hereby grants to you a non-exclusive, non-transferable, non-assignable license (without right to sublicense) under Luminex's copyrights and trade secrets to use the SOFTWARE on a single computer running with a single unit of a specific model of Luminex instrument, as such model is identified on the packaging included with the SOFTWARE. For certain SOFTWARE that is not integrated into a Luminex instrument and provided on a separate medium and/or does not require activation, you may make one (1) copy of the SOFTWARE for backup or archival purposes only. For some of such SOFTWARE, you may also install the SOFTWARE on up to two (2) additional computers for purposes of performing ancillary tasks (i.e. preparing templates/protocols, performing further analysis or re-running previous data), provided such computers are at a single location and are NOT connected with a Luminex instrument. In addition, you may purchase the right to use the SOFTWARE on additional computers, as agreed to in writing with Luminex or its authorized reseller, for purposes of performing ancillary tasks (i.e. preparing templates/protocols, performing further analysis or re-running previous data), provided such computers are at a single location and are NOT connected with a Luminex instrument. Although no rights or licenses under any of Luminex's patents are granted by or shall be implied from the license of the SOFTWARE or the sale of a Luminex instrument to you, the purchaser, you may obtain a license under Luminex's patents, if any, to use a Luminex instrument with microsphere beads or cassettes, as applicable, authorized by Luminex, or with kits developed, manufactured, and distributed by licensees authorized in writing by Luminex, by purchasing such beads, cassettes, or kits from Luminex or an authorized Luminex reseller or licensee.

4. **RESTRICTIONS.**
   a. SOFTWARE must only be installed and operated on a single computer running with or in connection with a Luminex instrument, as set forth above.
b. You may not use this SOFTWARE for any commercial purpose, including in the performance of testing services, unless expressly agreed to in writing by Luminex or as authorized in writing by Luminex through an authorized reseller of the SOFTWARE.
c. You may only use the SOFTWARE with microspheres or cassettes, as applicable, authorized by Luminex or with kits developed, manufactured and distributed by licensees authorized in writing by Luminex.
d. You must maintain all proprietary notices on all copies of the SOFTWARE.
e. You may not distribute copies of the SOFTWARE to third parties.
f. You may not reverse-engineer, decompile, disassemble, or otherwise attempt to derive source code from the SOFTWARE.
g. You may not copy (other than one backup or archival copy), sell, distribute, sublicense, rent, lease, transfer or grant any rights in or to all or any portion of the SOFTWARE.
h. You must comply with all applicable laws and regulations, including Food and Drug Administration requirements, regarding the use of the SOFTWARE.
i. You may not modify or prepare derivative works of the SOFTWARE, including modifying any branding or graphics.
j. You may not use the SOFTWARE in a computer-based service business, in the operation of a service bureau, or otherwise for the benefit of any third party, or publicly display visual output of the SOFTWARE.
k. You may not transmit the SOFTWARE over a network, by telephone, or electronically by any means.
l. You acknowledge your obligation to inform your employees, consultants, and associates who will be using the SOFTWARE, of Luminex’s labeling literature, warnings, instructions, notices, and other materials regarding proper use that Luminex has provided or may hereafter provide to you.

5. TERM AND TERMINATION. Your rights under this EULA are effective until termination. You may terminate this EULA at any time by destroying the SOFTWARE, including all computer programs and documentation, and erasing any copies residing on your computer equipment. Luminex may terminate this EULA upon thirty (30) days written notice to you. Your rights under this EULA automatically terminate without further action on the part of Luminex if you do not comply with any of the terms or conditions of this EULA. Upon any termination of this EULA, you agree to destroy the SOFTWARE and erase any copies residing on your computer equipment.

6. RIGHTS IN SOFTWARE. All rights and title in and to the SOFTWARE and any copies thereof are owned by Luminex or its suppliers. This EULA is not a sale and does not transfer to you any title or ownership interest in or to the SOFTWARE or any patent, copyright, trade secret, trade name, trademark or other intellectual property right therein. You shall not remove, alter, or obscure any proprietary notices contained on or within the SOFTWARE and shall reproduce such notices on any back-up copy of the SOFTWARE. All title and intellectual property rights in and to the content which may be accessed through use of the SOFTWARE is the property of the respective content owner and may be protected by applicable copyright or other intellectual property laws and treaties. This EULA grants you no rights to use such content.

7. EXPORT RESTRICTIONS. You agree that you will not export or re-export the SOFTWARE to any country, person, entity, or end-user subject to U.S.A. export restrictions or in a manner that is contrary to any local, provincial, state, national, international, and foreign laws or regulations applicable to you. You hereby warrant no state or federal agency has suspended, revoked, or denied your export privileges.

8. NO WARRANTY. THE SOFTWARE IS LICENSED “AS IS, WHERE IS.” ANY USE OF THE SOFTWARE IS AT YOUR OWN RISK WITHOUT WARRANTY OF ANY KIND. THE SOFTWARE IS PROVIDED FOR USE ONLY WITH LUMINEX PRODUCTS. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, LUMINEX AND ITS SUPPLIERS DISCLAIM ALL CONDITIONS, TERMS, REPRESENTATIONS, AND WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NONINFRINGEMENT OF INTELLECTUAL PROPERTY.

9. LIMITATION OF LIABILITY. IN NO EVENT SHALL LUMINEX, ITS AFFILIATES, LICENSORS, AUTHORIZED DISTRIBUTORS, OR SUPPLIERS BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS INFORMATION, OR ANY OTHER PECUNIARY LOSS) ARISING OUT OF THE USE OF OR INABILITY TO USE THE SOFTWARE, OR THE RESULTS OF THE USE OF THE SOFTWARE, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER LEGAL THEORY, AND EVEN IF LUMINEX, ITS AFFILIATES, LICENSORS, AUTHORIZED DISTRIBUTORS, OR SUPPLIERS HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. YOU ACKNOWLEDGE THAT THE “AS IS” AND LIMITATION ON LIABILITY PROVISIONS CONTAINED IN THIS AGREEMENT CONSTITUTE
Your Representation and Indemnity. You represent and warrant that you shall use the Software in accordance with the terms of this Agreement, and that any such use of the Software will not violate any law, regulation, judicial order or injunction. You agree to defend, indemnify and hold Luminex and its authorized resellers and licensors, and each of their respective officers, directors, employees, agents, successors and assigns harmless from and against any loss, damage, claim, cost, expense or other liability (including, without limitation, legal fees and amounts reasonably paid in settlement) suffered or incurred by Luminex as a result of any claim or cause of action by a third party arising out of, based upon or relating to: (i) your use of the SOFTWARE, (ii) your use of or reliance on any evaluation, analytic results or other data derived from the SOFTWARE, or (iii) any breach by you or any of your representatives of the terms of this Agreement.

Miscellaneous. This EULA is governed by the laws of the State of Texas, U.S.A., without reference to conflicts of laws principles. You shall not assign or sublicense or otherwise transfer the rights or license granted hereunder, by agreement or by operation of law, without the prior written consent of Luminex, and all assignments in violation of this prohibition shall be null and void. This EULA is the complete and exclusive agreement of Luminex and you and supersedes all other communications, oral or written, relating to the subject matter hereof. No change to this EULA shall be valid unless in writing and signed by the party against enforcement is sought. The waiver or failure of Luminex or you to exercise in any respect any right or rights provided for herein shall not be deemed a waiver of any further right hereunder. If any provision of this EULA is held unenforceable, the remainder of this EULA will continue in full force and effect.

Language. The parties hereto confirm their express wish that this Agreement, as well as all other documents related thereto, including notices, be drawn up in the English language only and declare themselves satisfied therewith; les parties aux présentes confirment leur volonté que cette convention, de même que tous les documents qui s'y rattachent, y compris tout avis, soient rédigés en langue anglaise et s'en déclarent satisfaits.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbols</td>
<td>iii</td>
</tr>
<tr>
<td>Intended Use</td>
<td>1</td>
</tr>
<tr>
<td>Product Description</td>
<td>1</td>
</tr>
<tr>
<td>Assay Workflow</td>
<td>1</td>
</tr>
<tr>
<td>Acceptable Specimens</td>
<td>2</td>
</tr>
<tr>
<td>Materials Provided</td>
<td>2</td>
</tr>
<tr>
<td>Software and CD Contents</td>
<td>2</td>
</tr>
<tr>
<td>Reagents Kit</td>
<td>3</td>
</tr>
<tr>
<td>Materials Required but not Provided</td>
<td>3</td>
</tr>
<tr>
<td>Personal Computer</td>
<td>4</td>
</tr>
<tr>
<td>Summary of Targets Detected by xMAP® MultiFLEX™ Zika RNA Assay</td>
<td>4</td>
</tr>
<tr>
<td>Warnings and Precautions</td>
<td>4</td>
</tr>
<tr>
<td>Instrument Setup</td>
<td>5</td>
</tr>
<tr>
<td>Instructions for Installing the xPONENT® Data Acquisition Protocol</td>
<td>5</td>
</tr>
<tr>
<td>Assay Procedure</td>
<td>5</td>
</tr>
<tr>
<td>Sample Preparation</td>
<td>6</td>
</tr>
<tr>
<td>RT-PCR Setup</td>
<td>6</td>
</tr>
<tr>
<td>Assay Hybridization</td>
<td>7</td>
</tr>
<tr>
<td>Data Analysis</td>
<td>9</td>
</tr>
<tr>
<td>Installing TDAS LSM for Zika</td>
<td>9</td>
</tr>
<tr>
<td>Verifying the Version of TDAS LSM for Zika</td>
<td>9</td>
</tr>
<tr>
<td>Analyzing Data with TDAS LSM for Zika</td>
<td>9</td>
</tr>
<tr>
<td>Results Interpretation</td>
<td>10</td>
</tr>
<tr>
<td>Assay Limitations</td>
<td>10</td>
</tr>
<tr>
<td>Performance Characteristics</td>
<td>11</td>
</tr>
<tr>
<td>Analytical Sensitivity - Limit of Detection</td>
<td>11</td>
</tr>
<tr>
<td>Determination of Preliminary Limit of Detection</td>
<td>11</td>
</tr>
<tr>
<td>Confirmation of the Limit of Detection (LoD)</td>
<td>12</td>
</tr>
<tr>
<td>Analytical Sensitivity- FDA Reference Material</td>
<td>12</td>
</tr>
<tr>
<td>Analytical Reactivity - Inclusivity</td>
<td>13</td>
</tr>
<tr>
<td>Exclusivity – Cross Reactivity</td>
<td>15</td>
</tr>
<tr>
<td>Interference Study</td>
<td>17</td>
</tr>
<tr>
<td>Co-infection/Competitive Interference Study</td>
<td>17</td>
</tr>
<tr>
<td>Clinical Evaluation</td>
<td>18</td>
</tr>
<tr>
<td>Technical Support</td>
<td>22</td>
</tr>
</tbody>
</table>
For In Vitro Diagnostic Use. 1

Intended Use

The xMAP® MultiFLEX™ Zika RNA Assay test is a RT-PCR test intended for the qualitative detection of RNA from the Zika virus in serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen) from individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated). Test is limited to U.S. laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests, and similarly qualified non - U.S. laboratories.

Test results are for the identification of Zika viral RNA. Zika virus RNA is generally detectable in serum and urine during the acute phase of infection and up to 14 days following onset of symptoms, if present. Positive results are indicative of current Zika virus infection. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude Zika virus infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The xMAP MultiFLEX Zika RNA Assay test is intended for use by trained clinical laboratory personnel qualified by state and federal regulations. Specific training on the use of the xMAP MultiFLEX Zika RNA Assay will be made available to end-users at their request. The test is only for use under the Food and Drug Administration’s Emergency Use Authorization. The xMAP MultiFLEX Zika RNA Assay is indicated for use on Luminex® IVD xMAP® instruments (MAGPIX® or Luminex® 200™).

Product Description

The xMAP® MultiFLEX™ Zika RNA Assay is a qualitative test intended for the detection of Zika virus RNA targets, as well as an internal control. The xMAP MultiFLEX Zika RNA Assay incorporates multiplex Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) in conjunction with the Luminex® xMAP® Technology for target detection. Luminex xMAP Technology uses the principles of fluidics, fluorescent-dyed microspheres, and digital signal processing to enable detection of up to 50 analytes per sample on a MAGPIX® instrument and up to 100 analytes per sample on a Luminex® 200™ instrument. xMAP Technology is used extensively in clinical diagnostics for applications in infectious disease, molecular genetics, pharmacogenetics, HLA, and autoimmune diseases.

The xMAP MultiFLEX Zika RNA Assay uses proprietary RT-PCR primers and probes in a panel designed for selective amplification of Zika Virus (6 distinct genomic regions). The 6 distinct Zika genomic regions allow for improved detection of the genetic variation of Zika virus. The panel also includes an internal control: MS2 (bacteriophage RNA extraction control).

Assay Workflow

The xMAP® MultiFLEX™ Zika RNA Assay workflow is shown in Figure 1 on page 1. Extract samples using a validated automated extraction method/system. Extracted total nucleic acid is then simultaneously amplified using target-specific primers and probes for RT-PCR, followed by amplicon hybridization to probe-coupled microspheres. Detection of the targets of interest are carried out with a Luminex® instrument after adding streptavidin-conjugated R-Phycoerythrin (SAPE).

FIGURE 1. xMAP® MultiFLEX™ Zika RNA Assay Workflow
Acceptable Specimens

- Serum (collected in a serum separator tube)
- Plasma (collected in a K3 EDTA tube)
- Urine (collected in specimen cup) and Serum (collected in a serum separator tube)
- Urine (collected in specimen cup) and Plasma (collected in a K3 EDTA tube)

**NOTE:** Urine alone is not an acceptable specimen type without a matched plasma or serum specimen.

Specimen Handling and Storage

- Separate the serum and plasma specimens according to standard laboratory procedures prior to freezing.
- When transporting human specimens, ensure that all applicable regulations for transport of potentially infectious biological specimens have been met.
- Transport/ship human specimens (serum, plasma, urine) in dry ice, if possible; otherwise use frozen cold packs.
- Process specimens immediately or store specimens at -20°C upon receipt. Thaw sample and keep on ice during sample processing. Store remaining sample at -70°C for long term storage. If specimens will not be tested within the same day of receipt, freeze the specimens immediately upon receipt at -70°C.
- Luminex does not recommend repeat freezing and thawing of specimens.

Materials Provided

Software and CD Contents

Refer to "Installing TDAS LSM for Zika" on page 9 for instructions to install and use the data analysis software, TDAS LSM for Zika (IVD-EUA). Ensure that the version of TDAS LSM for Zika specified on the carton containing kit reagents is the version used to analyze data generated with those reagents, unless notified otherwise.

Files provided on the Data Analysis Software LSM for xMAP® MultiFLEX™ Zika RNA Assay CD:

- Set-up executable that installs Data Analysis Software for xMAP MultiFLEX Zika RNA Assay
  - TDAS LSM for Zika
- Data acquisition protocols for xPONENT® software
- Example output files
- TDAS LSM for Zika (IVD-EUA) Version History
- TDAS LSM 2.4 Software User Manual
Reagents Kit

*Table 1* on page 3 outlines reagents supplied in the kit and their storage conditions.

**NOTE:** The kit includes 100 reactions worth of reagents.

**TABLE 1. Reagents Supplied in the Kit and Storage Conditions**

<table>
<thead>
<tr>
<th>Reagents</th>
<th>Volume per Tube</th>
<th>Storage Conditions</th>
<th>Shipping Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer Mix</td>
<td>500.0 µL</td>
<td>Store at -20°C, upon receipt</td>
<td>2°C to 8°C</td>
</tr>
<tr>
<td>Streptavidin-Phycoerythrin (SAPE)</td>
<td>30.0 µL</td>
<td>2°C to 8°C, protected from light</td>
<td>2°C to 8°C</td>
</tr>
<tr>
<td>Microsphere mix</td>
<td>1.0 mL</td>
<td>2°C to 8°C, protected from light</td>
<td>2°C to 8°C</td>
</tr>
<tr>
<td>Buffer A</td>
<td>3.0 mL</td>
<td>2°C to 8°C</td>
<td>2°C to 8°C</td>
</tr>
<tr>
<td>Buffer B</td>
<td>7.5 mL</td>
<td>2°C to 8°C</td>
<td>2°C to 8°C</td>
</tr>
<tr>
<td>MS2 bacteriophage RNA extraction control</td>
<td>1.5 mL</td>
<td>2°C to 8°C</td>
<td>2°C to 8°C</td>
</tr>
</tbody>
</table>

This kit is shipped at 2°C to 8°C. Upon receipt, the primer mix should be stored at -20°C. All other kit components should be stored at 2°C to 8°C.

**NOTE:** For a copy of the Safety Data Sheet (SDS), contact Luminex “Technical Support” on page 22.

Materials Required but not Provided

- MAGPIX® or Luminex® 200™ System with xPONENT® software, calibrators, and verifiers
- Automated nucleic acid extraction system, BioMerieux® NucliSENS® easyMAG®

**NOTE:** Follow the manufacturer instructions for extraction of DNA/RNA from the sample.

**NOTE:** There is a product recall for certain lots of easyMAG® extraction reagents. Though no shifts in performance associated with use of these reagents were observed when using them in combination with Luminex Corporation’s xMAP® MultiFLEX™ Zika RNA Assay, each lot of affected easyMAG extraction reagents should be evaluated at least weekly before use in extraction of diagnostic specimens. Laboratories should also closely monitor for any trend in Median Fluorescent Intensity (MFI) of the internal MS2 control and the external Zika virus positive control during testing. Laboratories should refer to BioMerieux® Product Safety Correction Notices for a list of impacted lots and advice for end users.

- QIAGEN® OneStep RT-PCR Kit (Catalog # 210210, 210212, or 210215)
- Thermal Cycler (Eppendorf® vapo.protect™ Mastercycler® pro S or Eppendorf® Mastercycler® ep gradient or equivalent)

**NOTE:** The thermal cycler should be able to run the thermal profile at 3°C/sec ramp rate.

- Pipettes (P10, P100, P200, and P1000)
- Vortex mixer
- Mini centrifuge
- Filtered pipette tips
- Bio-Rad® Microseal® ‘A’ film (Catalog # MSA5001), or equivalent
- USA Scientific® 0.2 mL PCR tubes (Catalog # 1402-3900)
- Bio-Rad Hard-Shell® Low-Profile Thin-Wall 96-Well Skirted PCR Plate (Catalog # HSP9601), or equivalent
xMAP® MultiFLEX™ Zika RNA Assay Package Insert

- Fisher Scientific DynaMag™-96 Side Skirted Magnet (Catalog # 12027), or equivalent
- PCR-Cooler rack (Catalog # Eppendorf 022510509), or equivalent
- RNase-free water
- External target specific controls, (optional)
- Sonicator bath (Ultrasonic Cleaner, Cole-Parmer®, Catalog # A-08849-00), or equivalent

Personal Computer
A personal computer with the following minimum requirements is required to run TDAS LSM:

- Operating System: Microsoft® Windows® 7
- CPU: 1 gigahertz (GHz) or faster processor
- Monitor: Resolution of 1024 x 768 pixels or better
- Memory: At least 256 megabytes (MB) of available memory
- Disk Space: At least 1 gigabyte (GB) of free space
- CD or DVD-ROM: At least 24X in speed

Summary of Targets Detected by xMAP® MultiFLEX™ Zika RNA Assay

### TABLE 2. Targets Detected

<table>
<thead>
<tr>
<th>Target</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zika Virus 1, conserved region 1</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>Zika Virus 2, conserved region 2</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>Zika Virus 3, conserved region 3</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>Zika Virus 4, conserved region 4</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>Zika Virus 5, conserved region 5</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>Zika Virus 6, conserved region 6</td>
<td>Detect Zika Virus</td>
</tr>
<tr>
<td>MS2</td>
<td>Extraction, RT-PCR amplification, and detection control</td>
</tr>
</tbody>
</table>

Warnings and Precautions

1. For In vitro diagnostic use under the Emergency Use Authorization only.
2. For prescription use only.
3. In the event of damage to the protective packaging, consult the Safety Data Sheet (SDS) for instructions.
4. Care should be taken when handling, storing, and disposing of potentially infectious materials. Suitable barrier protection against potential pathogens is recommended during all stages of use. Gloves and laboratory coats should be worn at all times. Adherence to appropriate local biosafety and biohazard guidelines or regulations is recommended when working with any human-derived blood, body fluids, tissues, or primary human cell lines where the presence of an infectious agent may be unknown. Handle waste disposal in accordance with accepted medical practice and applicable regulations.
6. This procedure should be performed under laboratory safety conditions that take into consideration the potential infectious nature of the serum specimens involved. At a minimum, Luminex recommends that these procedures be performed using BSL-2 facilities and practices. To ensure safety of laboratory personnel, perform all sample manipulations within a Class II (or higher) biological safety cabinet (BSC). Proper disposable gowns, gloves, and eye protection should be worn.
7. Fresh clean gloves must be worn in each area and must be changed before leaving that area.
8. Do not pipette by mouth.
9. For pre-analytical (sample extraction) steps, use the procedure that is provided with the sample extraction system.
10. The nucleic acid extraction procedure should be performed in a separate room from the room where RT-PCR amplification will be performed. The RT-PCR assay should be performed in a separate, template free room. During RT-PCR amplification, portions of the viral genomes are amplified. All original samples should be maintained separately from the PCR room to avoid contamination of samples.
11. Perform the procedure given in this package insert as described. Any deviation from the outlined protocols may result in assay failure or cause erroneous results.

Instrument Setup

Before using the Luminex® instrument for the data acquisition step, follow the procedures for preparation and calibration described in the xPONENT® for MAGPIX® Software User Manual or the xPONENT® for Luminex® 200™ Software User Manual.

If using the Luminex® 200™ instrument, manually adjust the probe height for the plate before running the assay.

If using the MAGPIX® instrument, perform the probe height adjustment using the hybridization plate (Bio-Rad® skirted plate) and one alignment sphere. In xPONENT®, the plate name MUST be saved as MBP_v-bottom plate.

Prior to hybridization, ensure that the Luminex instrument has been turned on, and run through the daily startup routine. Import the protocol and create a batch containing the appropriate samples for this assay. If using the MAGPIX®, adjust the probe height before turning the plate heater on. Also, ensure that the Luminex instrument plate heater has been set to 52°C.

Instructions for Installing the xPONENT® Data Acquisition Protocol

If the appropriate protocols are already installed on the computer controlling the Luminex® instrument where the assay is being run, skip the following steps.

1. Access the computer that controls the Luminex® system on which the assay will be run.
2. Insert the TDAS LSM for Zika CD into the CD drive of the computer.
3. Start the Luminex® xPONENT® software.
4. From within the Luminex xPONENT software, choose the Protocols page.
5. On the Protocols page, open the Protocols tab, then click Import. This launches the Open dialog box.
6. In the Open dialog box, browse to the Protocols for Luminex xPONENT folder on the CD.
7. Select the appropriate protocol file:
   a. If using Luminex® 200™, choose the xMAP MultiFLEX Zika RNA Assay_LX200[1].lxt protocol file, then click Open.
   b. If using Luminex® MAGPIX®, choose the xMAP MultiFLEX Zika RNA Assay_MAGPIX[1].lxt protocol file, then click Open.
8. Remove the CD.

Assay Controls

Good laboratory practices recommend using positive and negative controls to assure functionality of reagents and proper performance of the assay procedure.

External Negative Control (Extraction Control) - A confirmed negative sample control should be included in each nucleic acid extraction run/ batch. If the External Negative Control is positive, the specimens processed in the same extraction run should all be re-extracted.

No Template Control (RNase- DNase-free water) - No Template Controls (NTCs) for the amplification/ detection steps are DNase- and RNase free- distilled water in place of specimen nucleic acids and must be included in each assay run. A minimum of one NTC in each assay run is required to monitor for contamination and provide background signals necessary for data processing and making assay calls. The NTC is a control for contamination or improper function of the assay reagents which could result in false positive results.
Internal Control (Bacteriophage MS2) - This internal positive control is added to each test sample, as well as to each external control, prior to extraction. The internal control allows you to ascertain whether the extraction and reverse-transcription/amplification steps of the assay are functioning correctly.

External Positive Control - In addition to the provided MS2 bacteriophage internal control, additional External Positive Control material that is commercially available from Zeptometrix may be used with the xMAP® MultiFLEX™ Zika RNA Assay based on local guidelines or laboratory SOPs. Commercially available Zika culture fluid (PRVABC59) can be obtained from Zeptometrix (catalog # 0810525CF). This External Positive Control should be processed with the same workflow as clinical specimens. A positive result for the Zika virus specific viral RNA confirms the assay is performing as expected.

Assay Procedure

Sample Preparation
Extract specimens using the BioMerieux® NucliSENS® easyMAG®. Follow manufacturer instructions for instrument set up using the following parameters:

1. Add 5.0 µL of MS2 to 200.0 µL of every specimen and external control.
2. Select Generic 2.0.1 as the extraction protocol.
3. Select the sample type (for urine, select other).
4. Select 0.2 mL as sample input.
5. Select 25.0 µL as the elution volume.
6. Select primary (on-board) as the lysis method.

RT-PCR Setup
Follow the instructions below to set up and run RT-PCR reactions using the QIAGEN® OneStep RT-PCR Kit.

1. Enter the following RT-PCR program into the thermal cycler with a ramp rate of 3°C/second for all cycling conditions.

2. Prepare a master mix (MM) according to Table 3 on page 7. Volumes are for a single reaction.
   a. Multiply each volume by your desired number of reactions, plus one or more No Template Control (NTC) reaction to create an appropriately sized Master Mix.

   **NOTE:** Volumes do NOT include overage.
   • Vortex and centrifuge each reagent, except the enzyme, for 3 to 5 seconds.
   b. Keep the RT Enzyme Mix and the final Master Mix on a cold block while setting up the RT-PCR reactions. Avoid keeping RT-PCR reagents at room temperature for long periods of time.
   c. Vortex and centrifuge the Master Mix for 3 to 5 seconds before dispensing into individual PCR tubes.

   **NOTE:** To avoid carry-over contamination from previously amplified RT-PCR products that could potentially generate false positive calls, avoid setting-up RT-PCR Master Mix reactions in the same area where post-amplification is processed. Designate separate areas for pre-amplification and post-amplification, with separate pipettes and reagents. Do not store or add template in the area designated for pre-amplification set-up.
TABLE 3. Master Mix Volumes

<table>
<thead>
<tr>
<th>Reagents</th>
<th>Volume µL Per Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>QIAGEN® One-Step RT-PCR Buffer, 5X</td>
<td>5.0 µL</td>
</tr>
<tr>
<td>Primer Mix</td>
<td>5.0 µL</td>
</tr>
<tr>
<td>RNase-free water</td>
<td>3.0 µL</td>
</tr>
<tr>
<td>QIAGEN® One-Step 10 mM dNTP mix</td>
<td>1.0 µL</td>
</tr>
<tr>
<td>QIAGEN® One-Step RT-PCR Enzyme</td>
<td>1.0 µL</td>
</tr>
<tr>
<td><strong>Total Volume</strong></td>
<td><strong>15.0 µL</strong></td>
</tr>
</tbody>
</table>

**NOTE:** Volumes do NOT include overage.

3. Aliquot 15.0 µL of the Master Mix into the desired number of PCR tubes.
4. Add 10.0 µL of extracted sample (DNA/RNA) or RNase-free water into each PCR tube, using a different tip for each tube.
   **NOTE:** Avoid letting Master Mix and template sit at room temperature while adding template to individual PCR tubes. Use cold blocks to set up RT-PCR reactions.
5. Cap PCR tubes.
6. Vortex and centrifuge the PCR tubes for 5 seconds to ensure all reaction components are at the bottom of the PCR tubes.
7. Place the PCR tubes into the thermal cycler and run the RT-PCR program in Figure 2 on page 6.

Assay Hybridization

Follow the instructions below to hybridize the amplified product to Luminex® microspheres and read on the Luminex instrument (MAGPIX® or Luminex® 200™).

1. Ensure the instrument plate heater is set to 52°C prior to sample acquisition.
   **NOTE:** Refer to “Instrument Setup” on page 5 for more information regarding to instrument setup.
2. Vortex the stock microsphere mix for 5 to 10 seconds. Sonicate for 10 seconds.
3. Prepare a microsphere reaction that is sufficient for all samples and controls. Prepare the diluted microsphere mixture as follows:
   **NOTE:** Microsphere mixture is light sensitive. Care should be taken to minimize exposure to light.

TABLE 4. Diluted Microsphere Mix Volumes

<table>
<thead>
<tr>
<th>Reagents</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsphere Mix</td>
<td>10.0 µL</td>
</tr>
<tr>
<td>Buffer A</td>
<td>30.0 µL</td>
</tr>
<tr>
<td><strong>Total Volume</strong></td>
<td><strong>40.0 µL</strong></td>
</tr>
</tbody>
</table>

**NOTE:** Volumes do NOT include overage.

4. Obtain the Bio-Rad® 96-Well Skirted PCR Plate to run in your thermal cycler for the hybridization reaction.
5. Vortex the diluted microsphere mixture for 3 to 5 seconds.
6. Pipette 40 µL of the diluted microsphere mixture into each of the wells.
7. Centrifuge the RT-PCR product for 5 to 10 seconds before opening the tubes.
8. Pipette 10 µL of RT-PCR product into each well, using a different tip for each well. Pipette up and down 4 to 5 times to mix.
9. Seal the 96-well PCR plate with Microseal® 'A' film.
10. Incubate the 96-well PCR plate in a thermal cycler with the heated lid enabled, and program the following:

```
1 Cycle
95°C - 4 min
```

```
1 Cycle
52°C - 15 min
```

End
52°C - Hold

**NOTE:** During the incubation, prepare the fresh SAPE mixture. Remove the plate immediately after the 19-minute incubation.

11. Prepare a fresh SAPE mix sufficient for all samples and controls as follows:

**NOTE:** SAPE is light sensitive. Care should be taken to minimize exposure to light.

### TABLE 5. Diluted SAPE Volumes

<table>
<thead>
<tr>
<th>Reagents</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock SAPE</td>
<td>0.3 µL</td>
</tr>
<tr>
<td>Buffer B</td>
<td>74.7 µL</td>
</tr>
<tr>
<td><strong>Total Volume</strong></td>
<td><strong>75.0 µL</strong></td>
</tr>
</tbody>
</table>

**NOTE:** Volumes do NOT include overage.

12. Vortex the diluted stock SAPE for 3 to 5 seconds.
13. Remove the 96-well PCR plate from the thermal cycler. Carefully remove the Microseal 'A' film from the plate to avoid cross-contamination.
14. Place the 96-well PCR plate onto a magnetic plate separator and allow microspheres to separate into a pellet for 2 minutes.
15. Remove all supernatant from each well, using a different tip for each well. Take care not to disturb the microsphere pellet.
16. Remove the 96-well PCR plate from the magnetic plate separator.
17. Pipette 75 µL of freshly made SAPE dilution mixture into each well containing microspheres.
18. Resuspend the microsphere pellet by pipetting up and down 4 to 5 times.
19. Seal the 96-well PCR plate with a new Microseal 'A' film and return the plate to the thermal cycler, and program the following:

```
1 Cycle
52°C - 15 min
```

End
52°C - Hold

**NOTE:** Remove plate immediately after the 15 minute incubation.

20. Remove the 96-well PCR plate from the thermal cycler. Carefully remove the Microseal 'A' film from the plate to avoid cross-contamination.
21. Transfer the 96-well PCR plate directly to the pre-heated block on the Luminex instrument.

**NOTE:** Ensure that the Luminex instrument plate heater is pre-heated to 52°C before running the assay.
22. Analyze the plate using the included xPONENT® protocol.
Data Analysis

Once the data is acquired from the previous steps, an output file is created under the Luminex® batch run folder. Use the Data Analysis Software (TDAS LSM for Zika) to analyze this file.

Installing TDAS LSM for Zika

NOTE: Skip this section if the proper version of TDAS LSM for Zika is already installed.

To install the software, complete the following:

1. Ensure that you have sufficient Windows® administrative privileges to install software on the computer.
2. Insert the TDAS LSM for Zika CD.
3. Launch My Computer.
4. Browse to the CD drive, then double-click TDAS LSM for Zika set-up.
5. Follow the on-screen instructions to complete the installation.

Verifying the Version of TDAS LSM for Zika

To confirm that the correct version of TDAS is installed, complete the following.

1. Double-click the TDAS LSM for Zika icon. The Log-on TDAS LSM for Zika dialog box opens. Ensure that the TDAS version in the dialog box matches the software version on the kit label.
2. Log into TDAS LSM for Zika. Use a password if password protection was enabled during installation.
3. On the Help menu, click About TDAS....
4. Verify that the correct software version appears in the About TDAS LSM for Zika dialog box.
5. Verify that the installed assay is the xMAP® MultiFLEX™ Zika RNA Assay.
   
   NOTE: Verifying the installed assay is critical for proper analysis.

6. Click Close in the About TDAS LSM for Zika dialog box.
7. If the above steps fail, uninstall the software. Follow the steps in the “Installing TDAS LSM for Zika” on page 9 procedure to re-install the software.
8. Remove the CD.

Analyzing Data with TDAS LSM for Zika

To perform data analysis, complete the following:

1. Verify that the Luminex® output file is accessible by the computer where TDAS LSM for Zika is installed.
2. Launch TDAS LSM for Zika on your computer through Start > All Programs or by double-clicking the desktop icon.
3. On the File menu, click Open.
4. Browse and click on the output file. Ensure that TDAS LSM for Zika recognized the selected file and will analyze it using the xMAP® MultiFLEX™ Zika RNA Assay (IVD-EUA) configuration file.
5. Click Open.
6. If the batch data is opened for the first time on the computer for analysis, identify the no template controls (NTC).
   a. In the Identify Samples dialog box, choose the Sample ID for each NTC. (Click the Sample ID again to clear.)
   b. Click Next.
7. Verify your NTC selections in the Confirmation dialog box. Confirm the selections by selecting check box All sample settings are correct.
   
   NOTE: Once the selections are confirmed and applied, all subsequent analyses of this batch data are performed using the settings selected for the first analysis. Click the Back button if modification is necessary.
8. Click Apply to see the analysis results.
Results Interpretation
All interpretation of test results must be performed using Data Analysis Software LSM (TDAS LSM for Zika) in conjunction with the xMAP® MultiFLEX™ Zika RNA Assay configuration file.

Target Calls
- POS: Zika virus RNA detected.
- NEG: Zika virus RNA not detected.
- No Call: there is a failure in one or more assay parameters/controls.

Control Calls
- PRES: the recommended Internal Control is detected.
- ABS: the recommended Internal Control is not detected.
- No Call: unable to determine presence or absence of the Internal Control due to an assay-specific criterion not being met.

Using TDAS LSM for Zika, controls and individual test sample results are then interpreted according to the following algorithm.

- Consider all targets for the negative control(s).
  - An External Negative Control (Extraction Control) should be included in each nucleic acid extraction run/batch. If the External Negative Control is positive, the specimens processed in the same extraction run should all be re-extracted.
  - If all of the NTCs fail to meet the criteria, then the plate fails. All samples will be labeled as “No Call”.
  - If any NTC meets all criteria, then the software will select the last successful control as the primary negative control and use this control to define background levels for the entire plate.
  - If any result is positive for any target for an NTC, then the run is considered invalid and should be re-run.
  - If all NTCs meet all criteria, then the plate will be considered free of contamination and all positive results for samples will be considered valid.

- Consider all targets for the External Positive Control
  - In addition, an External Positive Control may be used with the test based on local guidelines or laboratory SOPs. If the External Positive Control is negative, the specimens processed in the same extraction run should all be re-extracted.

- Consider all targets for samples.
  - If any result is positive for any target other than MS2, then the positive targets will be identified as “POS” and the target is considered “Detected” for that sample.
  - “Detected” results at least one of the six Zika virus specific target regions (beads) are considered Zika RNA positive.
  - If all non MS2 targets are negative for a sample, then consider MS2.
    - If MS2 is present, then all other targets will be identified as “NEG” and no targets are detected for that sample.
    - If MS2 is absent, then all other targets are identified as “No Call” for that sample and the sample fails.

NOTE: A patient matched serum specimen is required for serological follow up testing of all Zika virus RNA negative results, per the CDC testing algorithm. (Found at http://www.cdc.gov/zika/index.html).

Assay Limitations
1. All results should be interpreted by a trained professional in conjunction with the review of the patient's history, clinical signs, and symptoms.
2. The assay is for In vitro diagnostic use under the FDA Emergency Use Authorization (EUA) and is limited to U.S. laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests, and similarly qualified non-U.S. laboratories only.
3. Interpretation of results must account for the possibility of false-negative and false-positive results.
4. False positive results can be caused by:
   - Contamination with previously amplified nucleic acids
For In Vitro Diagnostic Use.

• Carry-over from samples processed in the same batch
5. False negative results can be caused by:
  • Poor sample collection
  • Degradation of viral nucleic acids during shipping or storage
  • Specimen collection prior to symptom onset
  • Specimen collection after the viremic phase (up to 14 days post-onset of symptoms for serum samples)
  • Failure to follow assay procedures
  • Use of unauthorized extraction method or platform
6. Adverse interfering effects have been observed on detecting low levels of Zika virus RNA when elevated levels of Dengue 2 virus RNA are also present in the same specimen.
7. Negative results do not preclude infection and should not be used as the sole basis of patient treatment/management decisions.
8. Proper collection, storage, and transport of samples are critical for achieving accurate results.
9. Extraction of nucleic acid from clinical specimens must be performed with the specified extraction methods listed in this procedure. Extraction methods not listed in this procedure have not been evaluated for use with this assay.
10. All specimens should be handled as if they are infectious. Proper biosafety precautions must be used.
11. Performance has only been established with the specimen types listed in the “Intended Use” on page 1. Other specimen types are not acceptable for use with this assay.
12. The Luminex® xMAP® MultiFLEX™ Zika RNA Assay described here has not been extensively tested with clinical specimens. Modifications of these assays (i.e., use of platforms or chemistries other than those described) is not permitted. These assays should not be further distributed without the explicit consent from Luminex.
14. This test cannot rule out diseases caused by other bacterial or viral pathogens.

Performance Characteristics

Analytical Sensitivity - Limit of Detection
The Limit of Detection (LoD) for Zika virus (Asian lineage) using the xMAP® MultiFLEX™ Zika RNA Assay was established and verified in a series of studies.

Limit of Detection (LoD) for Zika virus on the xMAP MultiFLEX Zika RNA Assay was determined evaluating a Zika virus strain of the Asian Zika virus lineage.

  • Zika Virus Asian lineage strain H/PF/2013 - Zika standard #1, inactivated. GenBank ID KJ776791.1 provided by European Virus Archives (EVA Marseille, France).

Determination of Preliminary Limit of Detection
The Zika virus initial stock concentration was determined using the titer provided by the vendor of 5.5 x 10^6 copies RNA/200 µL. The Zika virus was quantified by the vendor in TCID_{50} before inactivation and then the stock concentration was determined by the vendor in RNA copies by qRT-PCR after inactivation. The Zika virus standard was spiked into 200 µL of negative human serum, plasma, and urine. Serial dilutions were prepared, followed by nucleic acid purification of 200 µL input volume on the BioMérieux® NucliSENS® easyMAG® extraction system followed by a 25 µL elution. From this elution, 10 µL eluate was used as input into the xMAP® MultiFLEX™ Zika RNA Assay RT-PCR reaction. The assay was performed and then detected on MAGPIX® system. Each concentration was extracted, amplified and hybridized in triplicate (n=3). The lowest concentration at which all 3 replicates were detected was used to determine the preliminary Zika LoD concentration.
TABLE 6. **Determination of the Preliminary LoD**

<table>
<thead>
<tr>
<th>Target</th>
<th>Matrix</th>
<th>Dilution Factor</th>
<th>Testing Concentration Copies/mL</th>
<th>Call Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zika virus (strain H/PF/2013) Stock at 5.5 x 10^6 copies RNA/200uL</td>
<td>Serum</td>
<td>1:40,000</td>
<td>687</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:160,000</td>
<td>172</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:320,000</td>
<td>86</td>
<td>1/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:640,000</td>
<td>43</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>Plasma</td>
<td>1:12,649</td>
<td>2,174</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:40,000</td>
<td>687</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:126,491</td>
<td>217</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:400,000</td>
<td>68</td>
<td>1/3</td>
</tr>
<tr>
<td></td>
<td>Urine</td>
<td>1:40,000</td>
<td>687</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:160,000</td>
<td>172</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:320,000</td>
<td>86</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:640,000</td>
<td>43</td>
<td>3/3</td>
</tr>
</tbody>
</table>

**Confirmation of the Limit of Detection (LoD)**

Based on the preliminary Zika LoD determination, a second study was performed by spiking the Zika virus standard stock into pooled negative human plasma, serum, and urine samples. Twenty (20) independent (n=20) extractions were performed as previously described, followed by amplifications, hybridizations, and analysis on the Luminex® 200™ and MAGPIX® instruments at the preliminary LoD concentration and at 2 to 3 fold lower. Replicates were considered positive if the Median Fluorescent Intensity (MFI) was greater than or equal to 150 MFI and greater than or equal to two times the MFI of the No Template Control (NTC).

The final LoD for Zika virus was confirmed in all matrices when the results of the 20 replicates were positive with a 95.0% Confidence Interval as presented in Table 7 on page 12. The LoD was established at a final concentration of 687 copies/mL of the Zika RNA.

TABLE 7. **Zika Virus (in Human Serum, Urine, and Plasma)**

<table>
<thead>
<tr>
<th>Matrix Tested</th>
<th>Conc. Tested</th>
<th>Number Positive/ Number Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVA Zika Virus Standard H/PF/2013 (copies/mL)</td>
<td>MAGPIX®</td>
<td>Luminex® 200™</td>
</tr>
<tr>
<td>Serum</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Serum</td>
<td>343</td>
<td>15/20</td>
</tr>
<tr>
<td>Urine</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Urine</td>
<td>343</td>
<td>17/20</td>
</tr>
<tr>
<td>Plasma</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Plasma</td>
<td>217</td>
<td>18/20</td>
</tr>
</tbody>
</table>

**Analytical Sensitivity- FDA Reference Material**

An analytical study was performed using reference material (S1 and S2) and a standard protocol provided by the FDA, which includes a LoD range finding study and a confirmatory LoD study, to evaluate the analytical sensitivity of the xMAP® MultiFLEX™ Zika RNA Assay. The results are presented in Table 8 on page 13:
**TABLE 8. Summary of LoD Confirmation Results Using the FDA Reference Materials**

<table>
<thead>
<tr>
<th>Reference Materials</th>
<th>Specimen Type</th>
<th>Confirmed LOD* in RNA NAAT Detectable Units/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>Serum</td>
<td>3000</td>
</tr>
<tr>
<td>S1</td>
<td>Urine</td>
<td>3330</td>
</tr>
<tr>
<td>S2</td>
<td>Serum</td>
<td>5000</td>
</tr>
<tr>
<td>S2</td>
<td>Urine</td>
<td>5000</td>
</tr>
</tbody>
</table>

*Study performed according to the FDA issued protocol

**Analytical Reactivity - Inclusivity**

Inclusivity was evaluated for the xMAP® MultiFLEX™ Zika RNA Assay empirically with both African and Asian lineage Zika virus strains acquired from vendors. For the Martinique and ZIKV 2007 strains, stocks were prepared by spiking the acquired stock material with known titers into plasma, serum, and urine and serially diluted. Nucleic acid from each serially diluted stock was purified in triplicate (n=3) using 200 µL input volume on the BioMerieux® NucliSENS® easyMAG® extraction system, with a 25 µL elution. From this elution, 10 µL was used as input into the xMAP MultiFLEX Zika RNA Assay RT-PCR reaction. The MR766 Zika strain acquired from EVA was added directly to the xMAP MultiFLEX Zika RNA Assay RT-PCR reaction. The RT-PCR reaction was performed and detected with the MAGPIX® instrument in triplicate (n=3). The Zika virus concentrations were determined using the copies/mL provided by the vendor. The test results are shown in Table 9 on page 13.

**TABLE 9. Zika Inclusivity Empirical Testing Summary**

<table>
<thead>
<tr>
<th>Zika Strain Tested</th>
<th>Concentration (copies/mL)</th>
<th>Matrix</th>
<th>Number Positive/Number Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIKV 2007 - synthetic material from Sera Care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GenBank EU545988.1</td>
<td>1000</td>
<td>serum</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>serum</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>serum</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>plasma</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>plasma</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>plasma</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>urine</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>500</td>
<td>urine</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>urine</td>
<td>3/3</td>
</tr>
<tr>
<td>Zika virus - MRS_OPY_Martinique_PaRi_2015 (EVA / 33219)</td>
<td>700</td>
<td>serum</td>
<td>2/3</td>
</tr>
<tr>
<td>GenBank KJ647676</td>
<td></td>
<td>plasma</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>urine</td>
<td>3/3</td>
</tr>
<tr>
<td>Zika virus - MR 766 - BEI /NR-50065</td>
<td>30400</td>
<td>N/A</td>
<td>3/3</td>
</tr>
<tr>
<td>GenBank AY632535.2</td>
<td>9600</td>
<td>N/A</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>N/A</td>
<td>3/3</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>N/A</td>
<td>3/3</td>
</tr>
</tbody>
</table>

*In silico* analysis of the primer and probe sequences was performed to verify reagent sequence homology with each target region. A total of 28 current and historical Zika strains were selected for *in silico* analysis. For each Zika strain analyzed, at least one primer and probe set had sequences with >95.0% sequence identity. In addition, many Zika strains show a high degree of homology, with multiple primer and probe sets allowing for redundancy and assurance that false negative Zika results are not likely to occur.
### TABLE 10. Zika in silico Primer and Probe Sequence Identity Summary

|             | Zika 5 |  |  | Zika 6 |  |  | Zika 1 |  |  | Zika 2 |  |  | Zika 3 |  |  | Zika 3 modified |  |  | Zika 4 |  |  |  |  |
|-------------|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|
Exclusivity – Cross Reactivity

A panel of viruses and organisms known to cause similar signs and symptoms of the Zika virus infection were selected for analysis in the exclusivity/cross reactivity study for the xMAP® MultiFLEX™ Zika RNA Assay. Zika virus, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Chikungunya, West Nile, Yellow Fever, plasmodium falciparum, Parvo, and Mayaro were tested at high concentrations to monitor for cross reactivity with the assay primers and probes.

Dilutions were prepared by spiking tissue culture fluid purchased from a vendor (Zeptometrix) for each organism into negative human serum, plasma, and urine. Nucleic acid was purified with 200 µL input volume on the BioMerieux® NucliSENS® easyMAG® extraction system, with a 25 µL elution. From the elution, 10 µL was used as input into the xMAP MultiFLEX Zika RNA Assay RT-PCR reaction. The assay was performed and then detected with the MAGPIX® instrument. Each prepared sample was extracted, amplified and hybridized in triplicate (n=3). No cross reactivity was observed with any potential cross reacting organisms tested.

The data below demonstrates lack of cross reactivity among symptom-similar organisms in serum, plasma, and urine. Strains and concentrations tested are identified in Table 11 on page 15.

TABLE 11. Exclusivity Summary for (Serum, Plasma, and Urine)

<table>
<thead>
<tr>
<th>Specimen/Target</th>
<th>Concentration Tested/Unit</th>
<th>Zika Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue virus Type 1 - Hawaii</td>
<td>1 x 10^{4.39} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Dengue virus Type 2 - New Guinea</td>
<td>1 x 10^{4.39} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Dengue virus Type 3 - H87</td>
<td>1 x 10^{4.62} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Dengue virus Type 4 - H241</td>
<td>1 x 10^{5.53} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>West Nile virus - 1986</td>
<td>1 x 10^{4.82} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Yellow fever - 17D</td>
<td>1 x 10^{5.96} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Chikungunya – R80422</td>
<td>1:10 dilution N/A</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Plasmodium falciparum IPC 5202 - Battambang Cambodia 2011</td>
<td>1:10 dilution % infected cells</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Mayaro virus - TRVL 15537</td>
<td>1 x 10^{5.10} LD&lt;sub&gt;50&lt;/sub&gt;/gm in SM</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Parvo virus - B19</td>
<td>5 x 10&lt;sup&gt;5&lt;/sup&gt; IU/mL</td>
<td>No cross- reactivity</td>
</tr>
<tr>
<td>Zika Asian Lineage - PRVABC59</td>
<td>1 x 10^{4.34} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>Positive</td>
</tr>
<tr>
<td>Zika Asian Lineage - H/PF/2013</td>
<td>1 x 10^{5.16} TCID&lt;sub&gt;50&lt;/sub&gt;/mL</td>
<td>Positive</td>
</tr>
</tbody>
</table>
In *silico* evaluation of the analytical specificity was performed for each primer and probe sequence. BLAST® analysis queries of the primers were performed against the GenBank public domain nucleotide sequences and showed no significant combined (forward primer, reverse primer, and capture probe) homologies with other conditions that would predict potential false positive results. The BLAST algorithms were set to: blastn, word size 15, maximal target sequences 1000, match/mismatch scores 1,-2. All primers and probes were blasted individually.

In addition, *in silico* analysis (BLAST Results) for each of the organisms in Table 12 on page 16 was performed. The primer and probe sequences were blasted against selected species (viruses, bacteria, and parasites) and no significant cross-reactivity was identified based on the specific prediction rules applied in the *in silico* analysis.

**TABLE 12. Organisms Analyzed for *in silico* Cross Reactivity**

<table>
<thead>
<tr>
<th>Organism</th>
<th>Organism (taxid)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteria</strong></td>
<td></td>
</tr>
<tr>
<td>Borrelia burgdorferi</td>
<td>64895</td>
</tr>
<tr>
<td>Group A Strep</td>
<td>36470</td>
</tr>
<tr>
<td>Salmonella spp.</td>
<td>590</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>562</td>
</tr>
<tr>
<td>Leptospira spp.</td>
<td>171</td>
</tr>
<tr>
<td>Rickettsia spp.</td>
<td>780</td>
</tr>
<tr>
<td><strong>Trematodes</strong></td>
<td>Schistosoma spp.</td>
</tr>
<tr>
<td><strong>Protozoa</strong></td>
<td>Plasmodium vivax</td>
</tr>
<tr>
<td></td>
<td>Plasmodium spp.</td>
</tr>
<tr>
<td></td>
<td>Trypanosoma cruzi</td>
</tr>
<tr>
<td><strong>Flavivirus</strong></td>
<td>Zika (DENV and CHIKV)</td>
</tr>
<tr>
<td></td>
<td>Dengue (ZIKV and CHIKV)</td>
</tr>
<tr>
<td></td>
<td>WNV</td>
</tr>
<tr>
<td></td>
<td>YFV</td>
</tr>
<tr>
<td></td>
<td>SLEV</td>
</tr>
<tr>
<td></td>
<td>Spondweni virus</td>
</tr>
<tr>
<td></td>
<td>JEEV</td>
</tr>
<tr>
<td><strong>Alphavirus</strong></td>
<td>Chikungunya (ZIKV and DENV)</td>
</tr>
<tr>
<td></td>
<td>EEEV</td>
</tr>
<tr>
<td></td>
<td>WEEV</td>
</tr>
<tr>
<td></td>
<td>Ross River virus</td>
</tr>
<tr>
<td></td>
<td>Barmah Forest virus</td>
</tr>
<tr>
<td></td>
<td>O'nyong-nyong virus</td>
</tr>
</tbody>
</table>
Interference Study

Interference studies were not performed since conventional, well-established methods were used for both nucleic acid extraction and RT-PCR amplification.

Co-infection/Competitive Interference Study

To determine if competitive interference is present in the assay, co-infection studies were performed using EVA Zika Standard #1 H/PF/2013 spiked into two different matrices; serum and urine. Zika target was spiked at 3x LoD (2.06 x 10^3 copies/mL), while the co-infecting target was spiked at the highest concentration possible to determine potential interference.

Zika virus, near LoD, was detected in all triplicates along with the co-infected target in all case scenarios, except in the presence of high levels of Dengue virus type 2 when spiked in serum or urine matrices. This is expected because internal studies indicate that in the presence of high concentrations of Dengue virus type 2 (approximately at 1 x 10^5 TCID_{50}/mL), the RT-PCR demonstrates limited amplification for Zika targets in the panel at concentrations close to their LoD. No cross-reactivity with non-intended targets was observed.

In order to establish the assay's ability for low level Zika virus detection in the presence of high concentrations of Dengue virus type 2, contrived co-infected titration was performed by spiking EVA Zika Std1 at 3x LoD and Dengue virus type 2 at different concentrations to determine at which Dengue type 2 viral loads Zika RNA is detected.

Dual detection of co-infected specimens with Zika at concentrations near the LoD and high concentration of Dengue virus type 2 can be achieved when Dengue type 2 viral loads are as high as 10^{3.6} TCID_{50}/mL in both serum and urine matrices. Dengue type 2 viral loads higher than this will preclude detection of low levels of Zika in specimens containing both targets.

Bridging Studies

To demonstrate equivalence among three matrices (serum, plasma, and urine) and to demonstrate equivalence between the MAGPIX® and Luminex® 200™ systems, the LoD study was repeated using all three matrices and both systems. The results are shown in Table 13 on page 18. Additional matrix equivalency was also demonstrated during LoD range finding, inclusivity, and exclusivity studies as described in prior sections.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Organism (taxid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles virus</td>
<td>11234</td>
</tr>
<tr>
<td>Rubella virus</td>
<td>11041</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>10358</td>
</tr>
<tr>
<td>VZV</td>
<td>10335</td>
</tr>
<tr>
<td>Epstein-Barr virus</td>
<td>10376</td>
</tr>
<tr>
<td>HIV</td>
<td>11676</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12092</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>10407</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>11102</td>
</tr>
<tr>
<td>Enterovirus</td>
<td>12059</td>
</tr>
<tr>
<td>Adenovirus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>108098</td>
</tr>
<tr>
<td></td>
<td>130310</td>
</tr>
<tr>
<td></td>
<td>129951</td>
</tr>
<tr>
<td></td>
<td>565302</td>
</tr>
<tr>
<td></td>
<td>10519</td>
</tr>
</tbody>
</table>
TABLE 13. **Matrix (serum, urine, and plasma) and Instrument (MAGPIX® and Luminex® 200™) Equivalence**

<table>
<thead>
<tr>
<th>Matrix Tested</th>
<th>Conc. tested</th>
<th>Number positive/ number Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVA Zika Virus Standard H/PF/2013 (copies/mL)</td>
<td>MAGPIX®</td>
<td>Luminex® 200™</td>
</tr>
<tr>
<td>Serum</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Serum</td>
<td>343</td>
<td>15/20</td>
</tr>
<tr>
<td>Urine</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Urine</td>
<td>343</td>
<td>17/20</td>
</tr>
<tr>
<td>Plasma</td>
<td>687</td>
<td>20/20</td>
</tr>
<tr>
<td>Plasma</td>
<td>217</td>
<td>18/20</td>
</tr>
</tbody>
</table>

**Clinical Evaluation**

Clinical performance was evaluated with a combination of retrospective specimens and contrived samples.

**Zika Clinical Testing**

Matched human serum, urine, and plasma specimens were procured from a commercial source. Matched human specimens were collected in the Dominican Republic from 35 individual patients suspected of Zika virus infection. Plasma samples from these patients were found to be Zika virus RNA positive by the vendor using an RT-PCR assay. Samples were collected from patients between 1-7 days post-onset of symptoms.

The specimens were analyzed using a Zika virus real-time RT-PCR test under an EUA as the comparator method.

TABLE 14. **Zika Human Clinical Testing Results**

<table>
<thead>
<tr>
<th>Sample ID (1043-TDS)</th>
<th>xMAP® MultiFLEX™ Zika RNA Assay</th>
<th>Comparator Method (Ct Values)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Urine</td>
<td>Serum</td>
</tr>
<tr>
<td>0180</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0183</td>
<td>NEG</td>
<td>POS</td>
</tr>
<tr>
<td>0184</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0197</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0203</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0206</td>
<td>POS</td>
<td>NEG</td>
</tr>
<tr>
<td>0208</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0211</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0216</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0223</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0228</td>
<td>POS</td>
<td>NEG</td>
</tr>
<tr>
<td>0230</td>
<td>POS</td>
<td>NEG</td>
</tr>
<tr>
<td>0257</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0263</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0190</td>
<td>NEG</td>
<td>POS</td>
</tr>
</tbody>
</table>
Seven Zika virus RNA negative serum specimens were identified by the comparator method. In addition, 99 individual expected Zika virus RNA negative serum specimens collected from U.S. patients by a U.S. vendor were tested using the xMAP® MultiFLEX™ Zika RNA Assay.

A total of 20 contrived Zika samples were also prepared by spiking Zika strain H/PF/2013 into individual serum samples. Ten (10) samples were prepared at 2x LoD (low), seven samples were prepared at 4x LoD (mid), and three samples were prepared at 10x LoD (high). These contrived serum samples were used to supplement the 28 individual Zika virus RNA positive clinical serum specimens (as determined by the comparator method) for a total of 48 Zika positive serum samples.

Using the xMAP MultiFLEX Zika RNA Asssay, Zika virus RNA was detected at very low levels in two specimens (specimen 0220 and 0221) of the 106 negative clinical specimens. Zika virus was detected in all 20 contrived serum positives and 26 out of 28 natural clinical positive serum specimens. The comparator method gave high CT values of 39.2 and 38.5 for the two serum specimens (specimen 0206 and 0232) which were not detected in the xMAP MultiFLEX Zika RNA Assay.

<table>
<thead>
<tr>
<th>Sample ID (1043-TDS)</th>
<th>xMAP® MultiFLEX™ Zika RNA Assay</th>
<th>Comparator Method (Ct Values)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Urine</td>
<td>Serum</td>
</tr>
<tr>
<td>0195</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0218</td>
<td>NEG</td>
<td>POS</td>
</tr>
<tr>
<td>0232</td>
<td>POS</td>
<td>NEG</td>
</tr>
<tr>
<td>0254</td>
<td>NEG</td>
<td>POS</td>
</tr>
<tr>
<td>0182</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0196</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0201</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0214</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0220</td>
<td>NEG</td>
<td>POS</td>
</tr>
<tr>
<td>0221</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0226</td>
<td>NEG</td>
<td>NEG</td>
</tr>
<tr>
<td>0231</td>
<td>POS</td>
<td>NEG</td>
</tr>
<tr>
<td>0238</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0243</td>
<td>NEG</td>
<td>POS</td>
</tr>
<tr>
<td>0247</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0255</td>
<td>NEG</td>
<td>NEG</td>
</tr>
<tr>
<td>0265</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0269</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0270</td>
<td>POS</td>
<td>POS</td>
</tr>
<tr>
<td>0224</td>
<td>POS</td>
<td>POS</td>
</tr>
</tbody>
</table>

For In Vitro Diagnostic Use.
TABLE 15. Clinical Evaluation Results for Detecting Zika Virus RNA in Human Serum

<table>
<thead>
<tr>
<th>Serum Category</th>
<th>Number Tested</th>
<th>xMAP® MultiFLEX™ Zika RNA Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Zika Positive Serum Specimens (as determined by comparator result in serum)</td>
<td>28</td>
<td>Zika Positive: 26/28, Zika Negative: 2/28</td>
</tr>
<tr>
<td>Contrived Zika Positive (2x LoD)</td>
<td>10</td>
<td>Zika Positive: 10/10, Zika Negative: 0/10</td>
</tr>
<tr>
<td>Contrived Zika Positive (4x LoD)</td>
<td>7</td>
<td>Zika Positive: 7/7, Zika Negative: 0/7</td>
</tr>
<tr>
<td>Contrived Zika Positive (10x LoD)</td>
<td>3</td>
<td>Zika Positive: 3/3, Zika Negative: 0/3</td>
</tr>
<tr>
<td>Zika Negative Clinical Serum Specimens from U.S. Donors</td>
<td>99</td>
<td>Zika Positive: 0/99, Zika Negative: 99/99</td>
</tr>
<tr>
<td>Zika Negative Clinical Serum Specimens (as determined by comparator from suspected cases in endemic areas)</td>
<td>7</td>
<td>Zika Positive: 2/7, Zika Negative: 5/7</td>
</tr>
</tbody>
</table>

Positive Percent Agreement: 95.8% (46/48), 95.0% CI: 85.1% - 99.5%

Negative Percent Agreement: 98.1% (104/106), 95.0% CI: 93.4% - 99.5%

Eight (8) Zika virus RNA negative urine specimens were identified by the comparator method. In addition, 54 individual negative urine specimens collected from U.S. patients by a U.S. vendor were tested using the xMAP MultiFLEX Zika RNA Assay.

A total of 25 contrived Zika urine samples also were prepared by spiking Zika strain H/PF/2013 into individual urine samples. Twelve (12) samples were prepared at 2x LoD (low), 8 samples were prepared at 4x LoD (mid), and 5 samples were prepared at 10x LoD (high). These contrived urine samples were used to supplement the 27 individual Zika virus RNA positive clinical urine specimens (as determined by the comparator method) for a total of 52 Zika positive urine samples.

Using the xMAP MultiFLEX Zika RNA Assay, Zika virus RNA was detected at very low levels in two specimens (specimen 0206 and 0208) of the 63 negative clinical urine specimens. Zika virus RNA was detected in 24 out of 25 contrived urine positives and 26 out of 28 natural clinical positive urine specimens. The comparator method gave CT values of 39.4 and 37.8 for the two urine specimens (specimen 0226 and 0255) which were not detected in the xMAP MultiFLEX Zika RNA Assay.
TABLE 16. Clinical Evaluation Results for Detecting Zika Virus RNA in Human Urine

<table>
<thead>
<tr>
<th>Urine Category</th>
<th>Number Tested</th>
<th>xMAP® MultiFLEX™ Zika RNA Assay</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Zika Positive Urine Specimens (as determined by comparator result in urine)</td>
<td>28</td>
<td>26/28</td>
<td>2/28</td>
<td></td>
</tr>
<tr>
<td>Contrived Zika Positive (2x LOD)</td>
<td>12</td>
<td>11/12</td>
<td>1/12</td>
<td></td>
</tr>
<tr>
<td>Contrived Zika Positive (4x LOD)</td>
<td>8</td>
<td>8/8</td>
<td>0/8</td>
<td></td>
</tr>
<tr>
<td>Contrived Zika Positive (10x LOD)</td>
<td>5</td>
<td>5/5</td>
<td>0/5</td>
<td></td>
</tr>
<tr>
<td>Zika Negative Clinical Urine Specimens from US donors</td>
<td>54</td>
<td>0/54</td>
<td>54/54</td>
<td></td>
</tr>
<tr>
<td>Zika negative Urine Specimens as determined by comparator from suspected Zika cases in endemic areas</td>
<td>8</td>
<td>2/8</td>
<td>6/8</td>
<td></td>
</tr>
</tbody>
</table>

Positive Percent Agreement 94.3% (50/53) 95.0% CI: 84.6% - 98.1%

Negative Percent Agreement 96.8% (60/62) 95.0% CI: 89.3% - 99.1%

Additional analysis was performed based on the comparator method’s call algorithm whereby a positive result for either serum or urine (patient matched specimens) results in a positive patient infected status. Thirty-four (34) out of 35 patients were confirmed positive by having either a positive serum or urine result in the comparator test. Based on the xMAP® results using serum, and urine, the xMAP MultiFLEX Zika RNA Assay had one false positive (specimen 0220) and two false negatives (specimen 0226 and 0255) when compared to the comparator method. Based on the xMAP results using plasma and urine, the xMAP MultiFLEX Zika RNA Assay had no false positives and one false negative (specimen 0226) when compared to the comparator.

One Zika negative was identified by the comparator’s call algorithm. In addition, performance data generated from testing 99 individual expected Zika virus negative serum specimens (collected from U.S. patients by a U.S. vendor) using the xMAP MultiFLEX Zika RNA Assay was also included in this additional analysis.
### TABLE 17. Clinical Evaluation Results for xMAP Zika RNA Clinical Call Based on Serum, and Urine

| Specimen Category                                                                 | Number Tested | xMAP® MultiFLEX™ Zika RNA Assay |            |            |
|-----------------------------------------------------------------------------------|---------------|----------------------------------|------------|
| Natural Zika Positive Patient Result (as determined by comparator patient infected status) | 34            | Zika Positive: 32/34       | Zika Negative: 2/34 |
| Zika Negative Patient Results from US donors                                        | 99            | Zika Positive: 1/99           | Zika Negative: 99/99 |
| Zika Negative Patient Results as determined by comparator patient infected status for suspected Zika cases in endemic areas. | 1             | Zika Positive: 1/1            | Zika Negative: 0/1 |
| **Positive Percent Agreement**                                                     |               | 94.1% (32/34)                 | 95.0% CI: 80.9% - 98.4% |
| **Negative Percent Agreement**                                                    |               | 99.0% (99/100)                | 95.0% CI: 94.6% - 99.8% |

### TABLE 18. Clinical Evaluation Results for xMAP Zika RNA Clinical Call Based on Plasma, and Urine

| Specimen Category                                                                 | Number Tested | xMAP® MultiFLEX™ Zika RNA Assay |            |            |
|-----------------------------------------------------------------------------------|---------------|----------------------------------|------------|
| Natural Zika Positive Patient Result (as determined by comparator patient infected status) | 34            | Zika Positive: 33/34       | Zika Negative: 1/34 |
| Zika Negative Clinical Patient Results from US donors                              | 99            | Zika Positive: 0/99           | Zika Negative: 99/99 |
| Zika negative Patient Results as determined by comparator patient infected status for suspected Zika cases in endemic areas. | 1             | Zika Positive: 0/1            | Zika Negative: 1/1 |
| **Positive Percent Agreement**                                                     |               | 97.1% (33/34)                 | 95.0% CI: 85.1% - 99.5% |
| **Negative Percent Agreement**                                                    |               | 100.0% (100/100)              | 95.0% CI: 96.3% - 100.0% |

### Technical Support

Phone: 512-381-4397  
Toll Free: 1-877-785-2323  
International: + 800-2939-4959  
Fax: 512-219-5114  
Email: support@luminexcorp.com